On Wednesday, Acadia Healthcare Company Inc (NASDAQ:ACHC)’s shares inclined 2.11% to $79.98.
Acadia Healthcare Company, Inc. (ACHC) declared that it has accomplished the formerly declared acquisition of Belmont Behavioral Health from not-for-profit Einstein Healthcare Network. The attained assets comprise primarily of an inpatient behavioral healthcare facility with 147 beds serving the greater Philadelphia, Pennsylvania market.
In addition, Acadia declared the acquisition of The Manor Clinic, a 15-bed residential rehabilitation facility in Southampton, which is primarily focused on addictions treatment.
Joey Jacobs, Chairman and Chief Executive Officer of Acadia, remarked, “We are happy to start the second half of 2015 with the completion of two acquisitions that position Acadia well in growth markets. The completion of the Belmont Behavioral Health transaction strengthens our presence in Pennsylvania and gives us our first inpatient behavioral health facility in Philadelphia. It also reflects the ongoing opportunities we have for additional transactions with non-profit healthcare providers.
Acadia Healthcare Company, Inc. develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, and substance abuse facilities providing outpatient behavioral healthcare services to serve the behavioral health and recovery needs of communities in the United States, the United Kingdom, and Puerto Rico.
Check Point Software Technologies Ltd. (NASDAQ:CHKP)’s shares gained 0.83% to $80.21.
Check Point Software Technologies Ltd. (CHKP) the largest pure-play security vendor globally, recently declared the results of its 2015 Annual General Meeting. The company presented six proposals for the shareholders vote at the meeting, counting reappointment of the company’s directors and auditors, and the seventh proposal was withdrawn. About 142 million shares, representing about 78% of the shares outstanding as of the record date, were voted at the meeting.
All proposals voted on at the Annual General Meeting were adopted by an overwhelming majority vote of the shareholders.
Check Point would like to thank shareholders for the support and confidence they have in the company and its employees and for their vote at the Annual General Meeting.
Check Point Software Technologies Ltd. develops, markets, and supports a range of software, combined hardware, and software products and services for information technology (IT) security worldwide. It offers a portfolio of network security, endpoint security, data security, and administration solutions.
At the end of Wednesday’s trade, B/E Aerospace Inc (NASDAQ:BEAV)‘s shares dipped -1.06% to $54.32.
B/E Aerospace Inc (BEAV) B/E Aerospace has been under pressure, and traders are using options to manage the risk.
optionMONSTER’s Heat Seeker monitoring program detected the purchase of 3,000 October 60 calls yesterday, most of which priced for $3.60. Volume was almost 43 times open interest at the strike, so new money was put to work.
BEAV fell 0.96 percent to $59.69 yesterday and has lost 6 percent of its value since that poor quarterly report. Administration cited the effects of a strong U.S. dollar at the time. The company, whose products comprise aircraft seats and galleys, also fell after announcing results on Jan. 29.
Yesterday’s October 60s will provide exposure to the next earnings report in late July. Total option volume in the name was 10 times greater than average in the session, with calls accounting for a bullish 91 percent of the total.
B/E Aerospace, Inc. designs, manufactures, sells, and services cabin interior products for commercial aircraft and business jets in the United States and internationally. Its Commercial Aircraft segment offers first class, business class, tourist class, and regional aircraft seats, as well as spares; oxygen storage, distribution, and delivery systems for commercial and business jet aircraft; coffee makers/water boilers, ovens, and refrigeration equipment; and modular lavatory, wastewater, and galley systems.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), ended its Wednesday’s trading session with -1.15% loss, and closed at $1.72.
AVEO Pharmaceuticals, Inc. (AVEO) declared that it has received written feedback from the U.S. Food and Drug Administration regarding a potential pivotal study for tivozanib in the treatment of NRP-1 low colorectal cancer (CRC). Tivozanib is an oral, potent, selective inhibitor of vascular endothelial growth factor (VEGF) with a long half-life and activity against all three VEGF receptors.
AVEO recently presented results from the BATON-CRC study, a 265 patient randomized trial exploring the combination of mFOLFOX6 and tivozanib or bevacizumab as first-line treatment in patients with advanced metastatic CRC, at the 2015 American Association for Cancer Research (AACR) Tumor Angiogenesis and Vascular Normalization Conference. Among the predefined biomarkers explored in this study, neuropilin-1 (NRP-1), a signaling protein known to bind to VEGF-A in serum, was found to be a potential prognostic marker for angiogenesis inhibitor activity and may be predictive of tivozanib activity relative to bevacizumab.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. Its product candidates under development comprise Tivozanib, an tyrosine kinase inhibitor for various vascular endothelial growth factors; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which has accomplished Phase II trial; and AV-203, an anti-ErbB3 monoclonal antibody that has accomplished a Phase I dose escalation study.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
